Applying ONCO-RADS to Whole-body MRI Cancer Screening in a Retrospective Cohort of Asymptomatic Individuals

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2024 Feb 7

PMID 38326850

Authors

Yong-Sin Hu

Chia-An Wu

Dao-Chen Lin

Po-Wei Lin

Han-Jui Lee

Lo-Yi Lin

Chung-Jung Lin

Affiliations

Soon will be listed here.

Abstract

Background: Whole-body magnetic resonance imaging (WB-MRI) has emerged as a valuable tool for cancer detection. This study evaluated the prevalence rates of cancer in asymptomatic individuals undergoing WB-MRI according to the Oncologically Relevant Findings Reporting and Data System (ONCO-RADS) classifications in order to assess the reliability of the classification method.

Methods: We retrospectively enrolled 2064 asymptomatic individuals who participated in a WB-MRI cancer screening program between 2017 and 2022. WB-MRI was acquired on a 3-T system with a standard protocol, including regional multisequence and gadolinium-based contrast agent-enhanced oncologic MRI. Results of further examinations, including additional imaging and histopathology examinations, performed at our institute were used to validate the WB-MRI findings. Two radiologists blinded to the clinical outcome classified the WB-MRI findings according to the ONCO-RADS categories as follows: 1 (normal), 2 (benign finding highly likely), 3 (benign finding likely), 4 (malignant finding likely), and 5 (malignant finding highly likely). Firth logistic regression analysis was performed to determine the associations between participant characteristics and findings of ONCO-RADS category ≥ 4.

Results: Of the 2064 participants with median age of 55 years, 1120 (54.3%) were men, 43 (2.1%) had findings of ONCO-RADS category ≥ 4, and 24 (1.2%) had confirmed cancer. The cancer prevalence rates were 0.1%, 5.4%, 42.9%, and 75% for ONCO-RADS categories 2, 3, 4, and 5, respectively. In the multivariable model, older age (OR: 1.035, p = 0.029) and history of hypertension (OR: 2.051, p = 0.026), hepatitis B carrier (OR: 2.584, p = 0.013), or prior surgery (OR: 3.787, p < 0.001) were independently associated with the findings for ONCO-RADS category ≥ 4.

Conclusions: The ONCO-RADS categories for cancer risk stratification were validated and found to be positively correlated with cancer risk. The application of ONCO-RADS facilitates risk-based management after WB-MRI for cancer screening.

Citing Articles

The Whole-Body MRI Reporting and Data System Guidelines for Prostate Cancer (MET-RADS-P), Multiple Myeloma (MY-RADS), and Cancer Screening (ONCO-RADS).

Parillo M, Mallio C Cancers (Basel). 2025; 17(2).

PMID: 39858056 PMC: 11763526. DOI: 10.3390/cancers17020275.

References

Petralia G, Koh D, Attariwala R, Busch J, Eeles R, Karow D . Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. Radiology. 2021; 299(3):494-507. DOI: 10.1148/radiol.2021201740. View

Jafri W, Kamran M . Hepatocellular Carcinoma in Asia: A Challenging Situation. Euroasian J Hepatogastroenterol. 2020; 9(1):27-33. PMC: 6969322. DOI: 10.5005/jp-journals-10018-1292. View

Hoang J, Langer J, Middleton W, Wu C, Hammers L, Cronan J . Managing incidental thyroid nodules detected on imaging: white paper of the ACR Incidental Thyroid Findings Committee. J Am Coll Radiol. 2014; 12(2):143-50. DOI: 10.1016/j.jacr.2014.09.038. View

Zugni F, Padhani A, Koh D, Summers P, Bellomi M, Petralia G . Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: review and recommendations. Cancer Imaging. 2020; 20(1):34. PMC: 7216394. DOI: 10.1186/s40644-020-00315-0. View

Cieszanowski A, Maj E, Kulisiewicz P, Grudzinski I, Jakoniuk-Glodala K, Chlipala-Nitek I . Non-contrast-enhanced whole-body magnetic resonance imaging in the general population: the incidence of abnormal findings in patients 50 years old and younger compared to older subjects. PLoS One. 2014; 9(9):e107840. PMC: 4178037. DOI: 10.1371/journal.pone.0107840. View

Goehde S, Hunold P, Vogt F, Ajaj W, Goyen M, Herborn C . Full-body cardiovascular and tumor MRI for early detection of disease: feasibility and initial experience in 298 subjects. AJR Am J Roentgenol. 2005; 184(2):598-611. DOI: 10.2214/ajr.184.2.01840598. View

MacMahon H, Naidich D, Goo J, Lee K, Leung A, Mayo J . Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology. 2017; 284(1):228-243. DOI: 10.1148/radiol.2017161659. View

Rednam S, Erez A, Druker H, Janeway K, Kamihara J, Kohlmann W . Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res. 2017; 23(12):e68-e75. DOI: 10.1158/1078-0432.CCR-17-0547. View

Davenport M . Incidental Findings and Low-Value Care. AJR Am J Roentgenol. 2023; 221(1):117-123. DOI: 10.2214/AJR.22.28926. View

10.

Hegenscheid K, Seipel R, Schmidt C, Volzke H, Kuhn J, Biffar R . Potentially relevant incidental findings on research whole-body MRI in the general adult population: frequencies and management. Eur Radiol. 2012; 23(3):816-26. DOI: 10.1007/s00330-012-2636-6. View

11.

Gibson L, Paul L, Chappell F, Macleod M, Whiteley W, Salman R . Potentially serious incidental findings on brain and body magnetic resonance imaging of apparently asymptomatic adults: systematic review and meta-analysis. BMJ. 2018; 363:k4577. PMC: 6249611. DOI: 10.1136/bmj.k4577. View

12.

Ahlawat S, Debs P, Amini B, Lecouvet F, Omoumi P, Wessell D . Clinical Applications and Controversies of Whole-Body MRI: Expert Panel Narrative Review. AJR Am J Roentgenol. 2022; 220(4):463-475. DOI: 10.2214/AJR.22.28229. View

13.

Ramsey S, Yoon P, Moonesinghe R, Khoury M . Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention. Genet Med. 2006; 8(9):571-5. PMC: 2726801. DOI: 10.1097/01.gim.0000237867.34011.12. View

14.

Morin S, Cobbold J, Lim A, Eliahoo J, Thomas E, Mehta S . Incidental findings in healthy control research subjects using whole-body MRI. Eur J Radiol. 2008; 72(3):529-33. DOI: 10.1016/j.ejrad.2008.08.006. View

15.

Saya S, Killick E, Thomas S, Taylor N, Bancroft E, Rothwell J . Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. Fam Cancer. 2017; 16(3):433-440. PMC: 5487773. DOI: 10.1007/s10689-017-9965-1. View

16.

Villani A, Shore A, Wasserman J, Stephens D, Kim R, Druker H . Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016; 17(9):1295-305. DOI: 10.1016/S1470-2045(16)30249-2. View

17.

Lo G, Ai V, Au-Yeung K, Chan J, Li K, Chien D . Magnetic resonance whole body imaging at 3 Tesla: feasibility and findings in a cohort of asymptomatic medical doctors. Hong Kong Med J. 2008; 14(2):90-6. View

18.

Basar Y, Alis D, Sanli D, Akbas T, Karaarslan E . Whole-body MRI for preventive health screening: Management strategies and clinical implications. Eur J Radiol. 2021; 137:109584. DOI: 10.1016/j.ejrad.2021.109584. View

19.

Tabori U, Hansford J, Achatz M, Kratz C, Plon S, Frebourg T . Clinical Management and Tumor Surveillance Recommendations of Inherited Mismatch Repair Deficiency in Childhood. Clin Cancer Res. 2017; 23(11):e32-e37. DOI: 10.1158/1078-0432.CCR-17-0574. View

20.

Donner Y, Fortney K, Calimport S, Pfleger K, Shah M, Betts-LaCroix J . Great Desire for Extended Life and Health amongst the American Public. Front Genet. 2016; 6:353. PMC: 4718974. DOI: 10.3389/fgene.2015.00353. View